HTR3C

Across TCGA pan-cancer cohorts, HTR3C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HTR3C data layer compared with 21 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher HTR3C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HTR3C expression acts as an unfavorable survival marker.

BLCA, LUSC, and STAD are the cancer types where HTR3C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.128	0.549	<.001	33	view →
LUSC	OS	Median	II,III,IV	0.011	0.743	<.001	24	view →
STAD	DFS	Median	All	0.149	0.710	<.001	15	view →
LGG	OS	Median	All	0.195	0.896	<.001	12	view →
SKCM	OS	Median	III,IV	0.499	0.848	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HTR3C–BLCA (DFS)

Open the BLCA breakdown →